PATIENTS ACROSS ENGLAND AND WALES GAIN ACCESS TO NEW TREATMENT OPTION FOR MANTLE CELL LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING POSITIVE NICE DECISIONS

Contributed by: AstraZeneca

Tags

Cancer

Medicines

More Like This

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025